FOR RESEARCHERS
Research Funding Opportunities
Applications are now being accepted for the 2026 RRP-ALSF Research Accelerating RUNX1 Exploration (RARE) Grant
The RARE Grant supports research focused on identifying druggable oncogenic pathways and advancing cancer interception and prevention strategies toward clinical application. Funded projects will demonstrate clear potential to benefit patients and families affected by RUNX1-FPD.
Application Deadline: Thursday, December 11, 2025 before 8 p.m. ET
Coming Soon: RRP-ACS Leukemia Exploration and Prevention Grant Program (LEAP) Grant
The LEAP Grant aims to propel groundbreaking research in blood cancer interception and prevention for individuals affected by RUNX1-FPD. Focus areas include:
Deepening the understanding of biologic processes that drive the transition from clonal hematopoiesis to hematopoietic malignancies in RUNX1-FPD.
Supporting high-risk projects that pursue cancer interception treatments, including preclinical studies and clinical trials in RUNX1-FPD.
Eligibility
You work at a U.S. academic institution or an eligible non-profit.
You are a full-time independent investigator at any career stage.
Grant Terms
Applicants may only apply for one of the two funding mechanisms
1. LEAP-Research Scholar Grant
Intent: Supports an independent research project that aligns with one of the two LEAP program focus areas. Research Scholar Grants (RSGs) provide support for independent, self-directed researchers.
Term and Budget: Awards are for up to $215,000 per year for up to 4 years ($860,000 total direct costs) plus 10% allowable indirect costs.
2. LEAP-Team Award
Intent: Supports a team research project that aligns with one of the LEAP program research focus areas. The application must clearly articulate how the team will synergize to accelerate scientific advancement and clinical benefit.
Term and Budget: Team awards are for up to $430,000 per year direct costs for up to 4 years ($1,720,000 direct costs), plus 10% allowable indirect costs.
Key Dates
Anticipated Application Deadline: June 1, 2026
RRP Cancer Interception/ Prevention Research Roadmap
Our roadmap is simple. We only invest in research that brings us one step closer to our end goal. We understand that discovering medicines requires the right tools (i.e. disease models and laboratory reagents) and the right datasets (i.e. patient clinical and genomic data, as well as patient biospecimens). We have defined 4 rational therapeutic approaches to preventing blood cancer:
1) selectively targeting precancerous cells;
2) increasing RUNX1 activity;
3) decreasing cancer-causing inflammation;
4) fixing or replacing RUNX1-mutated cells using cell or gene therapy.
